Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.

Principal Investigator

Alan Kono

Study Number

F17185

Summary

This study is for people between the age 18 and 85 who have heart failure. The purpose of this study is to find out more about how an investigational study drug called Omecamtiv Mecarbil, works in people with heart failure when given in addition to the medications patients are already taking that help with heart failure. Omecamtiv Mecarbil is also known as AMG 423 and has been shown to increase the hearts ability to pump. This is a randomized study which means that participants will be assigned by chance (like flipping a coin) to receive either Omecamtiv Mercarbil or placebo (similar to a sugar pill). Patients are randomized to either Omecamtiv Mecarbil or placebo.

Phase

Phase III

Contact

Brian Aldrich

Available at the following location(s)

  • Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms

0